This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kane: In talking ...
The FDA has approved Johnson & Johnson’s supplemental new drug application for Caplyta among patients with schizophrenia at ...
Molecular profiling and prognosis of spindle cell/sclerosing rhabdomyosarcoma: A report from the Chinese PPOG trial. A phase Ib/II trial of radiotherapy combined with doxorubicin and PD-1 antibody for ...
Researchers discover a paradox: high cognitive performance predicts depressive relapse, contradicting traditional expectations.
SCOTTSDALE, AZ — In patients with Graves disease, prescribing a lower maintenance dose of methimazole (MMI) before discontinuing the drug is associated with significantly higher rates of remission, ...
Relapse prevention is why most people seek treatment, and with opioid use disorders (OUDs), there’s about a 90 percent relapse rate. This article explains why and how specific sayings from self-help ...
FDA label expansion adds relapse-prevention in adult schizophrenia, addressing a major driver of hospitalization, functional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results